PeptideLabs Logo
PeptideLabs
Documentación de Calidad
Back to all 64 profiles
Clinical researchEn investigación clínicaWADA

Community protocol · Cagrilintide

Cagrilintide: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: Amylin analogue · CagriSema component

Sources checked: 27 August 2026

Aviso importante de seguridad y responsabilidad

Esta página documenta y evalúa información de comunidades. No es consejo médico ni terapéutico, asesoramiento individual ni invitación al uso.

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

Cagrilintide

Se estudia solo y con semaglutida para la saciedad, el peso y el control de la glucosa.

Published study protocols are research procedures with inclusion and exclusion criteria. They are not instructions for unsupervised use.

Amounts, timing and cycles

Clinical research

Published study protocols are research procedures with inclusion and exclusion criteria. They are not instructions for unsupervised use.

Amount status

Trials use protocol-bound amounts and escalation; this does not create a safe community dose.

Profile evidence level: clinical.

Timing

Timing is set by each trial protocol and may differ substantially between studies.

No individual recommendation.

Cycle/duration

Duration is study-specific and ends according to protocol; long-term safety may remain unknown.

No individual recommendation.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Reconstitución y conversión U-100

Calculadora de reconstitución

For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.

Calculadora de reconstitución

Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.

Concentration

3,333.33 µg/ml

Calculated volume

0.06 ml

U-100 units

6 U

Calculated portions per vial

50

Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.

Mechanism and research questions

Long-acting amylin analogue

Cagrilintide is classified as “Long-acting amylin analogue”. Se estudia solo y con semaglutida para la saciedad, el peso y el control de la glucosa. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Análogo de amilina

Esto estudia cómo una señal similar a la amilina ralentiza el vaciado gástrico y aumenta la sensación de saciedad, actuando como una segunda señal de saciedad junto al GLP-1. Se miden, entre otras cosas, la cantidad de alimento por comida y la trayectoria del peso.

02

Resultados en glucosa y apetito

Los investigadores estudian cómo una sustancia cambia los niveles de glucosa en sangre y la sensación de hambre a lo largo del día, de forma similar a observar la saciedad tras distintas comidas. Las medidas habituales incluyen lecturas de glucosa en sangre y cuestionarios sobre hambre e ingesta.

03

Peso corporal y metabolismo

Los investigadores registran cambios en el peso corporal, la composición corporal y marcadores metabólicos como la glucosa o el colesterol a lo largo del estudio. Esto es similar a seguir el peso y los valores de laboratorio de una persona durante meses para observar tendencias generales en lugar de fluctuaciones diarias.

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Foros de control de peso

En estos foros, los usuarios comparan sus propias trayectorias de peso, efectos secundarios y cambios percibidos en el apetito entre diferentes productos. A menudo se comparten fotos de antes y después y cronogramas personales. Estos relatos y afirmaciones de marketing de proveedores no son prueba científica de eficacia.

Discusión de origen y pureza

Se discute qué proveedores se consideran más confiables y cómo difieren los resultados de las pruebas de pureza entre lotes. Estas evaluaciones comunitarias se basan en muestras limitadas y no reemplazan las pruebas de laboratorio independientes de cada lote individual.

Discusión de combinaciones y mezclas

Los usuarios intercambian combinaciones autoensambladas de varios péptidos y comparan los efectos percibidos, a menudo sin que la combinación específica haya sido estudiada nunca. Estas recomendaciones de combinaciones son opiniones personales, no protocolos verificados.

Adverse effects and risk boundaries

  • Según la diana pueden aparecer efectos gastrointestinales, deshidratación y cambios en glucosa o apetito; los fármacos incretínicos también pueden incluir advertencias biliares, pancreáticas y de retinopatía.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

  • El embarazo, los trastornos graves del vaciamiento gástrico y las enfermedades pancreáticas, biliares, renales o endocrinas requieren evaluación profesional; la ficha concreta puede añadir contraindicaciones.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Según la sustancia e indicación se revisan peso, presión arterial, hidratación, glucosa/HbA1c, función renal y hepática y medicación concomitante; los síntomas guían otras pruebas.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

En ensayos clínicos

La investigación, incluido su uso combinado con semaglutida, aún continúa.

Published evidence

La sustancia se está estudiando actualmente en ensayos clínicos estructurados en humanos, pero aún no existe una aprobación general.

La cagrilintida es un análogo de amilina que actúa a través de una vía de receptor distinta a la de los agentes GLP-1 como la semaglutida.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

En investigación clínica

Candidato en desarrollo clínico; no es un medicamento aprobado.

WADA 2026

This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile